Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Polyphor Ltd.
Sponsor:
Information provided by (Responsible Party):
Polyphor Ltd.
ClinicalTrials.gov Identifier:
NCT01837095
First received: April 2, 2013
Last updated: August 31, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)